Base Year
Historical Year
Forecast Year
The global neoantigen cancer vaccine market size was valued at USD 116.74 million in 2023, driven by the rising investments in the research and development of the immunotherapy and rapid technological advancements in the healthcare sector. The market size is anticipated to grow at a CAGR of 69.43% during the forecast period of 2024-2032 to achieve a value of USD 13,431.43 million by 2032.
Neoantigens are tumour-specific antigens produced in cancer cells that signify the changes which happen throughout the transformative process. These substances are truly unique to cancer tissue and have the potential to be identified by the immune system, resulting in the host's distinct anti-tumour activity. Neoantigens are peptides that are abnormally expressed as a result of genome alterations and are translated to form live peptides. They function as mechanisms for the immune system to distinguish between own and tumour tissue and have been identified as a novel target for cancer immunotherapies.
There are several key trends propelling the growth of the market size. The introduction of immunotherapy has emerged as a groundbreaking approach in cancer treatment and neoantigen cancer vaccines as a form of immunotherapy that specifically target neoantigens, which are tumour-specific antigens derived from genetic mutations has proven to be transformative in the approach to treat cancer. The increasing understanding of the immune system and its role in fighting cancer has fuelled the neoantigen cancer vaccines market demand further. The interest in neoantigen cancer vaccines has also spurred a significant increase in research and clinical trials which further has caused global neoantigen cancer vaccine market to witness dynamic growth.
Based on segments, the market is divided into product type, neoantigen type, route of administration, cell, technology, delivery mechanism, applications, and region.
Market Breakup by Product Type
Market Breakup by Neoantigen Type
Market Breakup by Route of Administration
Market Breakup by Cell
Market Breakup by Technology
Market Breakup by Delivery Mechanism
Market Breakup by Applications
Market Breakup by Region
The market has a lot of room to expand since immunotherapeutic treatment research and development is still ongoing, both in terms of understanding their mechanism of action, clinical relevance, and usability. The research and clinical trials in the field of immunotherapy is receiving enormous amounts of financial support from pharmaceutical corporations, biotech businesses, and academic institutions which has led to further growth capabilities for global neoantigen cancer vaccine market.
The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model, along with giving a SWOT analysis. The report gives a detailed analysis of the following neoantigen cancer vaccine companies, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Neoantigen Type |
|
| Breakup by Route of Administration |
|
| Breakup by Cell |
|
| Breakup by Technology |
|
| Breakup by Delivery Mechanism |
|
| Breakup by Applications |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of USD 116.74 million in 2023.
The market size is anticipated to grow at a CAGR of 69.43% during the forecast period of 2024-2032 to attain a value of around USD 13,431.43 million in 2032.
The growth of the market is driven by factors like rising investments in the research and development of the immunotherapy and rapid technological advancements in the healthcare sector.
The introduction of immunotherapy has emerged as a groundbreaking approach in cancer treatment and neoantigen cancer vaccines as a form of immunotherapy that specifically target neoantigens, which are tumour-specific antigens derived from genetic mutations has proven to be transformative in the approach to treat cancer.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
The different types of products in the market are personalized neoantigen vaccine and off-the shelf neoantigen vaccine.
The neoantigen types include synthetic long peptide (SLP), dendritic cell, nucleic acid, and tumour cell.
The route of administration can be categorised into intravenous, intramuscular, and transdermal, among others.
The cell types can be categorised into autologous and allogenic.
The different delivery mechanism in the market includes liposomes, virosomes, electroporation, and gene gun, among others.
The different technologies used in the market are RNA sequencing, whole genome sequencing, and HLA typing. among other.
The vaccine finds wide applications in the treatment of lung, melanoma, gastrointestinal, and brain cancer, among others.
Key players involved in the market includes OSE Immunotherapeutics SA, Gritstone bio, Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co. Inc., Moderna Inc., Avidea Technologies, Inc., Eli Lilly and Company, Vaccibody AS, Agenus Inc., Novogene Co., Ltd., ZIOPHARM Oncology Inc., ISA Pharmaceuticals B.V., BrightPath Biotherapeutics Co., Ltd., and BioNTech SE.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share